WHO ICTRP trial
A controlled randomized trial of transcatheter arterial chemoembolization…
ChiCTR-TRC-08000081 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-TRC-08000081 |
|---|---|
| Public title | A controlled randomized trial of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma |
| Scientific title | A controlled randomized trial of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma |
| Primary sponsor | FuJian Provincial Tumour Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | II (Phase II study) |
| Countries | China |
| Conditions | Hepatocellular carcinoma |
| Interventions | TACE+thalidomide group:Patients take thalidomide 100 mg/d for 7 days after TACE and take thalidomide 200 mg/d in succession;TACE group:TACE alone |
| Registration date | Mar 31, 2008 |
| Target size | TACE+thalidomide group:100;TACE group:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: